Kairos Pharma, LTD.

Our common stock is listed on the NYSE American LLC, or NYSE American, under the symbol “KAPA.”

Holders

As of April 14, 2025, we had 38 holders of record of our common stock and 16,693,306 shares of common stock issued and outstanding.

Dividends

We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into.

Securities authorized for issuance under equity compensation plans.

Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

Recent Sales of Unregistered Securities

See below “Recent Developments - January 2025 PIPE Offering.”

Issuer Purchases of Equity Securities

None.